Description
Background:
Cytokeratin 18 (CK18) is a structural protein predominantly expressed in epithelial cells, including hepatocytes. During liver injury and apoptosis, CK18 is cleaved by caspases, generating specific fragments such as CK18-M65. Elevated levels of CK18-M65 in serum are indicative of hepatocyte apoptosis and serve as a marker for liver injury and disease severity. The Human CK18-M65 ELISA Kit provides a reliable method for quantifying CK18-M65 concentrations in human serum samples, facilitating studies aimed at understanding liver pathophysiology, disease mechanisms, and therapeutic interventions.
Pathways and Relevance:
The Human CK18-M65 ELISA Kit is instrumental in elucidating pathways associated with hepatocyte apoptosis, inflammation, and fibrogenesis in liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), viral hepatitis, and liver fibrosis. By quantifying CK18-M65 levels, researchers can assess the extent of liver injury, monitor disease progression, and evaluate treatment responses. Furthermore, CK18-M65 serves as a prognostic marker for liver-related complications and mortality, highlighting its relevance in clinical practice and translational research.
Ongoing research endeavors include investigating the mechanisms underlying CK18-M65-mediated liver injury, identifying biomarkers for disease diagnosis and prognosis, and developing targeted therapies to attenuate hepatocyte apoptosis and fibrosis progression. Additionally, researchers are exploring the potential of CK18-M65 as a non-invasive biomarker for assessing treatment responses and predicting clinical outcomes in patients with liver diseases, driving innovation and shaping the future of hepatology and liver transplantation.
Validated against seven points for a “GOLD RING” Standard Quality ELISA – the benchmark sign for Krishgen Quality. The The GENLISA ELISA kits are used for assessing the specific biomarker in samples analytes which may be human serum, plasma, biological fluids and cell culture supernatant. The kit uses indirect sandwich assay with double antibodies – capture and detection to ensure a high degree of sensitivity and specificity in the estimation of Prostate Cancer Antigen 3 (PCA3);
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: kbiinfo@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!